Cite
HARVARD Citation
Bruix, J. et al. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389 (10064), pp. 56-66. [Online].